Commission Regulation (EC) No 869/2005 of 8 June 2005 amending Annexes I and II to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin as regards ivermectin and carprofen Text with EEA relevance
Date: 2005-06-08
Institutions: European Commission
Subjects: animal product, foodstuff, health policy, pharmaceutical legislation, pharmaceutical product, veterinary drug

9.6.2005

EN

Official Journal of the European Union

L 145/19

COMMISSION REGULATION (EC) No 869/2005

of 8 June 2005

amending Annexes I and II to Council Regulation (EEC) No 2377/90 laying down a Community
procedure for the establishment of maximum residue limits of veterinary medicinal products in
foodstuffs of animal origin as regards ivermectin and carprofen

(Text with EEA relevance)

THE COMMISSION OF THE EUROPEAN COMMUNITIES,

Having regard to the Treaty
Community,

establishing the European

Having regard to Council Regulation (EEC) No 2377/90 of 26
June 1990 laying down a Community procedure for the estab-
lishment of maximum residue limits of veterinary medicinal
products in foodstuffs of animal origin (1), and in particular
Articles 2 and 3 thereof,

Having regard to the opinions of
the European Medicines
Agency formulated by the Committee for Medicinal Products
for Veterinary Use,

Whereas:

(1)

(2)

All pharmacologically active substances which are used
within the Community in veterinary medicinal products
intended for administration to food-producing animals
should be evaluated in accordance with Regulation
(EEC) No 2377/90.

Ivermectin has been included in Annex I to Regulation
(EEC) No 2377/90 for bovine, porcine, ovine and Equidae
for liver and fat and for deer including reindeer for liver,
fat, muscle and kidney. That entry should be modified
and extended to all mammalian food producing species
excluding animals from which milk is produced for
human consumption.

(3)

Carprofen has been included in Annex I to Regulation
(EEC) No 2377/90 with carprofen as marker residue for
bovine and Equidae for muscle,
liver and kidney

fat,

excluding bovine from which milk is produced for
human consumption. That marker residue should be
replaced by the
carprofen and carprofen
glucuronide conjugate. Carprofen should be included in
Annex II to that Regulation for bovine milk only.

sum of

Regulation (EEC) No 2377/90 should be amended
accordingly.

An adequate period should be allowed before the applic-
ability of this Regulation in order to enable Member
States to make any adjustment which may be necessary
in the light of this Regulation to the marketing author-
accordance with Directive
isations
2001/82/EC of
the
Council of 6 November 2001 on the Community code
relating to veterinary medicinal products (2).

the European Parliament and of

granted

in

The measures provided for in this Regulation are in
accordance with
Standing
the
the
Committee on Veterinary Medicinal Products,

opinion

of

(4)

(5)

(6)

HAS ADOPTED THIS REGULATION:

Article 1

Annexes I and II to Regulation (EEC) No 2377/90 are amended
in accordance with the Annex to this Regulation.

Article 2

This Regulation shall enter into force on the third day following
its publication in the Official Journal of the European Union.

It shall apply from 8 August 2005.

This Regulation shall be binding in its entirety and directly applicable in all Member States.

Done at Brussels, 8 June 2005.

For the Commission

Günter VERHEUGEN
Vice-President

(1) OJ L 224, 18.8.1990, p. 1. Regulation as

last amended by
Commission Regulation (EC) No 712/2005 (OJ L 120, 12.5.2005,
p. 3).

(2) OJ L 311, 28.11.2001, p. 1. Directive as last amended by Directive

2004/28/EC (OJ L 136, 30.4.2004, p. 58).

L 145/20

EN

Official Journal of the European Union

9.6.2005

s
e
u
s
s
i
t

t
e
g
r
a
T

s
L
R
M

s
e
i
c
e
p
s

l
a
m
n
A

i

e
u
d
i
s
e
r

r
e
k
r
a
M

)
s
(
e
c
n
a
t
s
b
u
s

e
v
i
t
c
a

l

y
l
l
a
c
i
g
o
o
c
a
m
r
a
h
P

s
n
i
t
c
e
m
r
e
v
A

.

r
e
v
i
L

t
a
F

y
e
n
d
K

i

g
k
/
g

μ
0
0
1

g
k
/
g

μ
0
0
1

g
k
/
g

μ
0
3

g
n
i
c
u
d
o
r
p
-
d
o
o
f

n
a
i
l
a
m
m
a
m

l
l

A

a
1
B

)
1
(

s
e
i
c
e
p
s

n
i
t
c
e
m
r
e
v
a
-
o
r
d
y
h
D
-
3
2
2
2

i

,

n
i
t
c
e
m
r
e
v
I

‘

.

1
3
2

.

s
e
u
s
s
i
t

t
e
g
r
a
T

s
L
R
M

s
e
i
c
e
p
s

l
a
m
n
A

i

e
u
d
i
s
e
r

r
e
k
r
a
M

)
s
(
e
c
n
a
t
s
b
u
s

e
v
i
t
c
a

l

y
l
l
a
c
i
g
o
o
c
a
m
r
a
h
P

e
v
i
t
a
v
i
r
e
d

d
i
c
a

i

c
i
n
o
p
o
r
p
y
r
A

l

.

.

1
1
4

.

e
l
c
s
u
M

r
e
v
i
L

t
a
F

’

y
e
n
d
K

i

g
k
/
g

μ
0
0
5

g
k
/
g

μ
0
0
0
1

g
k
/
g

μ
0
0
0
1

g
k
/
g

μ
0
0
0
1

i

e
a
d
u
q
e

,
e
n
i
v
o
B

n
e
f
o
r
p
r
a
c

d
n
a

n
e
f
o
r
p
r
a
c

f
o

m
u
S

e
t
a
g
u
n
o
c

j

i

e
d
n
o
r
u
c
u
l
g

n
e
f
o
r
p
r
a
C

‘

)
1
(

e
n
i
v
o
B

s
e
i
c
e
p
s

l
a
m
n
A

i

)
s
(
e
c
n
a
t
s
b
u
s

e
v
i
t
c
a

l

y
l
l
a
c
i
g
o
o
c
a
m
r
a
h
P

s
t
n
e
g
a

y
r
o
t
a
m
m
a
l
f
n
i
-
i
t
n
A

.

8

’

.

y
l
n
o

k

l
i

m

e
n
i
v
o
b

r
o
F

)
1
(

n
e
f
o
r
p
r
a
C

‘

0
9
/
7
7
3
2

o
N

)

C
E
E
(

n
o
i
t
a
l
u
g
e
R

o
t

I
I

x
e
n
n
A

n

i

d
e
t
r
e
s
n

i

)
e
r
a
(
s
i

)
s
(
e
c
n
a
t
s
b
u
s

i

g
n
w
o

l
l

o
f

e
h
T

.

B

’

.

n
o
i
t
p
m
u
s
n
o
c

n
a
m
u
h

r
o
f

d
e
c
u
d
o
r
p

s
i

k

l
i

m

h
c
i
h
w

m
o
r
f

s
l
a
m
n
a

i

n

i

e
s
u

r
o
f

t
o
N

)
1
(

s
t
n
e
g
a

y
r
o
t
a
m
m
a
l
f
n
i
-
i
t
n
a

l
a
d
i
o
r
e
t
s
n
o
N

.

1
4

.

s
t
n
e
g
a

y
r
o
t
a
m
m
a
l
f
n
i
-
i
t
n
A

.

4

X
E
N
N
A

0
9
/
7
7
3
2

o
N

)

C
E
E
(

n
o
i
t
a
l
u
g
e
R

o
t

I

x
e
n
n
A

n

i

d
e
t
r
e
s
n

i

)
e
r
a
(
s
i

)
s
(
e
c
n
a
t
s
b
u
s

i

g
n
w
o

l
l

o
f

e
h
T

.

A

s
e
t
i
s
a
r
a
p
o
t
c
e

d
n
a

-
o
d
n
e

t
s
n
i
a
g
a

g
n
i
t
c
a

s
t
n
e
g
A

.

3
2

.

s
t
n
e
g
a

c
i
t
i
s
a
r
a
p
i
t
n
A

.

2